Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls

Pancreas

Volumn 42, Issue 7, 2013, Pages 1107-1113

  Carlsen, Anting Liu ^a   Joergensen, Maiken Thyregod ^b   Knudsen, Steen ^c   De Muckadell, Ove B Schaffalitzky ^b   Heegaard, Niels H H ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c Medical Prognosis Institute   (Denmark)

Author keywords

CA 19 9; MicroRNA; miRNA 375; pancreatic ductal adenocarcinoma

Indexed keywords

CA 19-9 ANTIGEN; MICRORNA; MICRORNA 100; MICRORNA 125B; MICRORNA 141; MICRORNA 146A; MICRORNA 148A; MICRORNA 155; MICRORNA 15A; MICRORNA 16; MICRORNA 17 5P; MICRORNA 196A; MICRORNA 196B; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 24; MICRORNA 29A; MICRORNA 30A 5P; MICRORNA 375; MICRORNA 423 5P; MICRORNA 513A 3P; MICRORNA 548B 5P; MICRORNA 92A; MICRORNA 99A; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CELL FREE SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MALE; MICROARRAY ANALYSIS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION;

ADULT; AGED; CA-19-9 ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; CELL-FREE SYSTEM; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 84885093528     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318296bb34     Document Type: Article

References (33)

1. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801-1806.
2. Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010;467:1109-1113.
3. Bauer AS, Keller A, Costello E, et al. Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue. PLoS One. 2012;7:e34151.
4. Zhang Y, Li M, Wang H, et al. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg. 2009;33:698-709.
5. Szafranska AE, Doleshal M, Edmunds HS, et al. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem. 2008;54:1716-1724.
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
7. Baffa R, Fassan M, Volinia S, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol. 2009;219:214-221.
8. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257-2261. (Pubitemid 43271657)
9. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-basedmarkers for cancer detection. Proc Natl Acad SciUS A. 2008;105:10513-10518.
10. Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila). 2009;2:807-813.
11. Morimura R, Komatsu S, Ichikawa D, et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer. 2011;105:1733-1740.
12. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249-264.
13. Flahault A, Cadilhac M, Thomas G. Sample size calculation should be performed for design accuracy in diagnostic test studies. J Clin Epidemiol. 2005;58:859-862. (Pubitemid 40966845)
14. Spurgeon SL, Jones RC, Ramakrishnan R. High throughput gene expression measurement with real time PCR in a microfluidic dynamic array. PLoS One. 2008;3:e1662.
15. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297:1901-1908. (Pubitemid 46707844)
16. Heegaard NH, Schetter AJ, Welsh JA, et al. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer. 2012;130:1378-1386.
17. Szafranska AE, Davison TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007;26:4442-4452. (Pubitemid 47014466)
18. Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007;120:1046-1054. (Pubitemid 46214304)
19. Nakata K, Ohuchida K, Mizumoto K, et al. MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis. Surgery. 2011;150:916-922.
20. Greither T, Grochola LF, Udelnow A, et al. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer. 2010;126:73-80.
21. Lee EJ, Baek M, Gusev Y, et al. Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. RNA. 2008;14:35-42.
22. Yabushita S, Fukamachi K, Tanaka H, et al. Circulating MicroRNAs in serum of human k-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas. Pancreas. 2012;41:1013-1018
23. Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13:423-433.
24. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108:5003-5008.
25. Gallo A, Tandon M, Alevizos I, et al. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One. 2012;7:e30679.
26. Baroukh NN, Van OE. Function of microRNA-375 and microRNA-124a in pancreas and brain. FEBS J. 2009;276:6509-6521.
27. Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129:1401-1414. (Pubitemid 46970709)
28. Avnit-Sagi T, Kantorovich L, Kredo-Russo S, et al. The promoter of the pri-miR-375 gene directs expression selectively to the endocrine pancreas. PLoS One. 2009;4:e5033.
29. Kapsimali M, Kloosterman WP, de Bruijn E, et al. MicroRNAs show a wide diversity of expression profiles in the developing and mature central nervous system. Genome Biol. 2007;8:R173.
30. Dai X, Chiang Y, Wang Z, et al. Expression levels of microRNA-375 in colorectal carcinoma. Mol Med Report. 2012;5:1299-1304.
31. Chang Y, Yan W, He X, et al. miR-375 Inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions. Gastroenterology. 2012;143:177-187.
32. Lu TX, Lim EJ, Wen T, et al. MiR-375 is downregulated in epithelial cells after IL-13 stimulation and regulates an IL-13Yinduced epithelial transcriptome. Mucosal Immunol. 2012;5:388-396.
33. Basu A, Alder H, Khiyami A, et al. MicroRNA-375 and microRNA-221: potential noncoding RNAs associated with antiproliferative activity of benzyl isothiocyanate in pancreatic cancer. Genes Cancer. 2011;2:108-119.